Page 5,345«..1020..5,3445,3455,3465,347..5,3505,360..»

WSU 2013 Pharmacy Honors Convocation – Comments of Dean Rick Slaughter – Video

Posted: Published on May 8th, 2013

WSU 2013 Pharmacy Honors Convocation - Comments of Dean Rick Slaughter By: RandyatWayne … Continue reading

Posted in Pharmacy | Comments Off on WSU 2013 Pharmacy Honors Convocation – Comments of Dean Rick Slaughter – Video

Chemo drug scandal: Pharmacy assistant that uncovered error says ‘It’s just part of our job’

Posted: Published on May 8th, 2013

The curiosity of a soft-spoken 28-year-old pharmacy assistant in Peterborough uncovered the medication error that went undetected at four other hospitals and saw more than 1,200 cancer patients receive diluted chemotherapy cocktails over the past year. Craig Woudsma noticed that bags of intravenous medication from Marchese Hospital Solutions, a new supplier to the Peterborough Regional Health Centre, had to be refrigerated, while those from the old supplier did not. It was enough to give Woudsma a feeling something was amiss. He compared the two labels and noticed the Marchese one had less information on it, and that the numbers didnt match the electronic worksheet with the patients individualized chemotherapy recipe. It just raised questions and, at any point during a process like this, you dont want to have questions, said Woudsma, testifying at a Queens Park social policy committee meeting where the diluted chemotherapy scandal is being investigated. A total of 1,205 Canadian cancer patients received diluted doses of chemotherapy medication over the past year. One-hundred-and-fifty patients have died since the diluted treatment began to be administered in February 2012. Its unclear what, if any, role the diluted medication played in their deaths. Hospitals have said Marchese supplied diluted bags … Continue reading

Posted in Pharmacy | Comments Off on Chemo drug scandal: Pharmacy assistant that uncovered error says ‘It’s just part of our job’

I'm no hero, says pharmacy worker who found diluted chemo drugs

Posted: Published on May 8th, 2013

A pharmacy assistant from the Ontario hospital that first detected watered down chemotherapy drugs was praised for his "keen eye," but he doesn't accept the label of "hero." "It's just part of the process, it's part of our job, and it just happens that this check that we made had a broader impact than we certainly would have anticipated," Craig Woudsma said Tuesday. "But definitely not a hero, no," he said. Speaking at a meeting of the Ontario legislature's standing committee on social policy, Woudsma, 28, of Peterborough Regional Hospital and senior pharmacy assistant Judy Turner described the chance discovery that revealed cancer drugs administered to 1,200 patients in Ontario and New Brunswick were diluted. The committee is looking into the oversight, monitoring and regulation of non-accredited pharmaceutical companies in the province. Last Tuesday, officials from the Peterborough hospital told committee members a red flag went up when an assistant checked the labels on IV bags provided by Marchese Hospital Solutions. It was the first day that the hospital used the new supplier. A staffer noticed a difference between Marchese's label for the chemo drug gemcitabine and the one from the previous supplier, Baxter. Woudsma said he began to question … Continue reading

Posted in Pharmacy | Comments Off on I'm no hero, says pharmacy worker who found diluted chemo drugs

Ontario pharmacy assistant who found chemo errors ‘not a hero,’ he says

Posted: Published on May 8th, 2013

An Ontario pharmacy assistant who discovered that chemotherapy drugs administered to more than 1,200 cancer patients in Ontario and New Brunswick were diluted says he doesnt consider himself a hero. Its just part of the process, its part of our job, and it just happens that this check that we made had a broader impact than we certainly would have anticipated, Craig Woudsma, 28, said on Tuesday. But definitely not a hero, no. Video: Orangutan's cancer treatment similar to humans The pharmacy team in the small Peterborough hospital that caught the problem did not want to go public with their story initially, hospital officials said. Were not looking for glory or anything like that, Mr. Woudsma told an Ontario legislative committee investigating the drug scare. What we do is kind of the same thing day in and day out, and were there for the patients. Mr. Woudsma, who was certified as pharmacy assistant in 2007 and started working in the hospitals oncology department in 2011, said he started asking questions when he saw the bags from Marchese Hospital Solutions required refrigeration. Another pharmacy assistant noticed that the bags containing the drug-and-saline mixture from the previous supplier, Baxter, did not need … Continue reading

Posted in Pharmacy | Comments Off on Ontario pharmacy assistant who found chemo errors ‘not a hero,’ he says

Talyst Partners with Bolton's Pharmacy to Offer InSite Remote Dispensing

Posted: Published on May 8th, 2013

KIRKLAND, Wash., May 8, 2013 -- Talyst partners with Bolton's Pharmacy, a privately owned pharmacy that services long-term care facilities. Bolton's will offer the Talyst InSite Remote Dispensing System in long-term care facilities to increase efficiency and reduce medication waste and errors. Bolton's Pharmacy offers a variety of services to ensure their customers receive the highest level of care including 24/7 "on-call" services, personal delivery of prepared medications, and personalized compounding of medications. "At Bolton's Pharmacy, we are continually perfecting our level of care," said Patricia Signore, president and owner of Bolton's Pharmacy. "InSite will revolutionize the way we provide pharmacist-approved medications to our facilities, ensuring even higher quality of care." "Bolton's Pharmacy is dedicated to their customers' needs," said Carla Corkern, Chief Executive Officer at Talyst. "InSite will help reduce waste, while providing residents access to medications 24/7/365, right at the facility." The InSite Remote Dispensing System enables secure, automated medication dispensing at the long-term care facilities to deliver pharmacist-approved, on-demand medications 24/7/365. It can quickly dispense pharmacist-approved medications right before each medication pass and on-demand to facilitate new residents, STAT orders, first doses, and PRNs. InSite virtually eliminates medication waste and reduces the number of trips to and … Continue reading

Posted in Pharmacy | Comments Off on Talyst Partners with Bolton's Pharmacy to Offer InSite Remote Dispensing

Seattle Genetics Reports First Quarter 2013 Financial Results

Posted: Published on May 8th, 2013

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) today reported financial results for the first quarter ended March 31, 2013. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities, progress with its antibody-drug conjugate (ADC) pipeline and technology and upcoming milestones. In 2013 we have continued to deliver on the ambitious goals we have set for ADCETRIS, our pipeline and our ADC technology, said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. We and our collaborator, Millennium: The Takeda Oncology Company, are bringing ADCETRIS to patients in need through approvals to date in the United States, Canada, European Union and Switzerland. In addition, across both corporate and investigator-sponsored studies, there are currently more than 20 ongoing ADCETRIS clinical trials, including four phase 3 studies. Seattle Genetics is also advancing several additional ADCs, including two programs planned for phase 1 trial initiations during 2013, while our collaborators continue to advance more than a dozen ADCs in clinical development. Recent ADCETRIS Highlights Other Recent Highlights Upcoming Milestones First Quarter Financial Results Total revenues in the first quarter of 2013 were $57.3 million, compared to $48.2 million in the first quarter of 2012. First quarter 2013 revenues … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Seattle Genetics Reports First Quarter 2013 Financial Results

BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional …

Posted: Published on May 8th, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, today announced the release of the enhanced LifeMap BioReagents portal (http://bioreagents.lifemapsc.com/) featuring an improved user interface, product descriptions, and customer support options, as well as the addition of new PureStem progenitor cells to the site. These novel progenitors provide new and unique tools for researchers to study developmental biology, tissue genesis and regenerative medicine, demonstrating purity in culture and unique gene expression. Among the new product offerings are novel PureStem progenitor cells such as the E72 cells capable of differentiating into betatrophin-expressing adipocytes, which may be useful in diabetes research. Via LifeMap BioReagents, researchers in academia, research hospitals, and biotech and pharma companies can access and purchase BioTimes research products, including PureStem human progenitor cells, PureStem packages, clinical and research grade human embryonic stem cell (hES) lines, culture media, and cell differentiation kits. As of April, the portal also offers select recombinant proteins, including growth factors, signaling molecules, differentiation factors, cytokines and chemokines that complement BioTimeresearch product lines. LifeMap BioReagents is integrated with LifeMaps integrated database suite products LifeMap Discovery, GeneCards and MalaCards, thereby providing all biomedical researchers accessing these databases a means of identifying stem cell reagents … Continue reading

Posted in Stem Cell Human Trials | Comments Off on BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional …

Stem cell researchers move toward treatments for rare genetic nerve disease

Posted: Published on May 8th, 2013

May 7, 2013 UCLA researchers led by Drs. Peiyee Lee and Richard Gatti at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have used induced pluripotent stem cells (iPSC) to advance disease-in-a-dish modeling of a rare genetic disorder, Ataxia Telangiectasia (A-T). Their discovery shows the positive effects of drugs that may lead to effective new treatments for the neurodegenerative disease. iPSC are made from patient skin cells rather than from embryos and can become any type of cells, including brain cells, in the laboratory. The study appears online ahead of print today in the journal Nature Communications. Patients with A-T begin life with neurological deficits that become devastating through progressive loss of function in a part of the brain called the cerebellum, which leads to severe difficulty with movement and coordination. A-T patients also suffer frequent infections due to their weakened immune systems and have increased cancer risk. A-T is caused by lost function in a gene, ATM, which normally repairs damaged DNA in the cells and preserves normal function. Laboratory mouse models are commonly used to study A-T; however, mice with A-T do not experience the more debilitating effects that humans do. In mice … Continue reading

Comments Off on Stem cell researchers move toward treatments for rare genetic nerve disease

VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue

Posted: Published on May 8th, 2013

SOUTH SAN FRANCISCO, CA--(Marketwired - May 7, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, announced that its high-quality, human pluripotent stem cell-derived cardiomyocytes (heart cells) were used by collaboration partner Duke University to grow a revolutionary three-dimensional (3D) human heart muscle. An abstract of the original research article published in Biomaterials, an international journal covering the science and clinical application of biomaterials, can be found online at: http://www.sciencedirect.com/science/article/pii/S0142961213004705. Researchers at Duke University combined VistaGen's human stem cell-derived heart cells with innovative tissue engineering and cardiac electrophysiology technologies to grow what is being called a "heart patch," which mimics the natural functions of native human heart tissue. This heart patch technology is being developed to aid in a better understanding of the biology critical to cardiac tissue engineering, for applications in regenerative cell therapy for heart disease, and as predictive in vitro assays for drug rescue and development. H. Ralph Snodgrass, PhD, VistaGen's President and Chief Scientific Officer, stated, "The developed contractile forces and other functional properties of these cardiac tissues are remarkable and are significantly higher than any previous reports. The achievement of successfully … Continue reading

Comments Off on VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue

The Alliance for the Advancement of Adult Stem Cell Therapy and Research Recently Has Proven Stem Cells To Be …

Posted: Published on May 8th, 2013

Bonita Springs, Florida (PRWEB) May 07, 2013 The Alliance for the Advancement of Stem Cell Therapy and Research monetarily supports some of the treatments provided by Intercellular Sciences. The Alliance is a non-profit organization dedicated to promoting research and treatment of life altering diseases with adult stem cells. Howie Linderman, founding board member of The Alliance, says, The Alliance is very proud to be a part of helping people obtain this breakthrough treatment. When I had my stem cell treatment in 2008, the process was much more complex. This new protocol will change the way the world views cardiac problems and we are excited to participate. To become a supporting member, please visit http://www.thestemcellalliance.org John C. and Eddie W. have had Dilated Cardiomyopathy for many years and as time has gone on their heart muscle has continued to weaken. The deterioration of their hearts function deteriorated to the point that walking across the room was impossible without shortness of breath. Eddie had become so bad that he was restricted to a wheelchair. Modern science has not been able to stop the progression of this devastating disease. All the medications and defibrillators can do is treat the symptoms. Both men were … Continue reading

Comments Off on The Alliance for the Advancement of Adult Stem Cell Therapy and Research Recently Has Proven Stem Cells To Be …

Page 5,345«..1020..5,3445,3455,3465,347..5,3505,360..»